Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed
ID: 351803Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $300K

Eligible Applicants

Unrestricted

Funding Category

Food and Nutrition

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 15, 2024 12:00 AM
  4. 4
    Due Apr 8, 2024 12:00 AM
Description

The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed". This grant aims to develop a methodology to integrate machine learning (ML) with computational fluid dynamics (CFD) models of orally inhaled drug products (OIDPs).

CFD has been widely used in developing and assessing generic inhaler devices as an alternative bioequivalence (BE) approach for OIDPs. However, there are still limitations in using CFD, such as computational time, limited grid resolution, and pre- and post-processing of large simulation data sets. ML has gained attention as a potential tool to address these limitations.

The purpose of this grant is to promote alternative BE studies and enhance the development and approval of generic OIDPs by integrating ML with CFD models. This integration will help alleviate the bottlenecks in CFD and accelerate the development process.

For more information about this grant opportunity, you can visit the following link: RFA-FD-24-005 Funding Opportunity Announcement.

Point(s) of Contact
Files
No associated files provided.
Similar Opportunities
Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed". This grant aims to develop and test an AI- or ML-based algorithmic Real-World Data (RWD) model for post-market surveillance of complex generic drug products. Complex generic drug products are becoming more prevalent in the generic marketplace and may have distinct user interface differences compared to reference listed drug (RLD) products. This funding opportunity seeks to address the need for a modernized post-market surveillance approach to compare clinical outcomes between complex generic products and their corresponding RLD products. The goal is to monitor for potential issues with therapeutic equivalence and inform regulatory decision making. The use of real-world data combined with machine learning (ML) and/or artificial intelligence (AI) can help efficiently identify post-market signals in an automated and repeatable manner. This will facilitate timely regulatory action. The FDA is looking for innovative proposals to develop and test an AI- or ML-based algorithmic RWD model that can effectively assess post-market clinical outcomes in patients switching among complex generic drug products and reference listed drugs. The grant has a funding ceiling of $300,000 and a floor of $300,000. It is expected that one award will be granted. The grant does not require cost sharing or matching. The category of funding activity is consumer protection, and the opportunity falls under the discretionary category. The grant is forecasted for the fiscal year 2024. Applicant organizations may submit more than one application, as long as each application is scientifically distinct. However, duplicate or highly overlapping applications will not be accepted. The FDA will not accept new applications that are submitted before the issuance of the summary statement from the review of an overlapping new or resubmission application. Similarly, resubmission applications cannot be submitted before the issuance of the summary statement from the review of the previous new application. Additionally, applications with substantial overlap with another application pending appeal of initial peer review will not be accepted. For more information and to apply for the grant, interested parties can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or by phone at 240-338-7494.
Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional". This funding opportunity falls under the category of Consumer Protection and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of the impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products. The grant has an award ceiling of $500,000 and an award floor of $250,000. It is expected that there will be 2 awards given. The eligible applicants for this grant opportunity are unrestricted, meaning any applicant organization may submit an application. However, each application must be scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. For more information and to apply for this grant opportunity, you can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The last updated date for this grant opportunity is November 30, 2023.